Drug Profile


Alternative Names: Buspirone/levodopa/carbidopa; Spinalon

Latest Information Update: 29 Jan 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Universite Laval
  • Developer National Institutes of Health (USA)
  • Class Antidepressants; Antiparkinsonians; Anxiolytics; Aromatic amino acids; Catecholamines; Hydrazines; Pyrimidines; Spiro compounds
  • Mechanism of Action Decarboxylase inhibitors; Dopamine receptor agonists; Serotonin 1A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Spinal cord injuries
  • Preclinical Multiple sclerosis

Most Recent Events

  • 28 Jan 2016 Preclinical trials in Multiple sclerosis in USA (PO)
  • 19 Jul 2013 Phase-I/II clinical trials in Spinal cord injuries in USA (PO)
  • 31 Dec 2009 Preclinical trials in Spinal cord injuries in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top